Clinical Trial

Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis

Study acronym: TOPICAL-MRI
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2025 (before its estimated April 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with alirocumab results in greater change from baseline in intracranial atherosclerotic plaque at week 26 than control in adults with acute ischemic stroke from intracranial atherosclerosis taking lipid lowering therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-08-09; most recent amendment 2025-03-23.
Status change: Recruiting → Active, Not Recruiting 2025-03-23
Status change: Not Yet Recruiting → Recruiting 2021-08-17
Trial Details
NCT Number NCT05001984
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: Chang Gung University
Conditions Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis
Enrollment 60 participants
Start Date 2021-08-01
Primary Completion 2025-04-15 (estimated)
Study Completion 2025-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-03-26